Headlands Technologies LLC Has $419,000 Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Key Points

• Headlands Technologies LLC reduced its stake in Hims & Hers Health by 80%, now holding 14,186 shares valued at $419,000.
• Farallon Capital Management significantly increased its position in the company by 64,338.5%, acquiring a total of 8,377,000 shares worth $202.56 million.
• Despite a strong year-over-year revenue growth of 72.6%, Hims & Hers reported a slight earnings miss, posting an EPS of $0.17 compared to analyst expectations of $0.18.

Headlands Technologies LLC decreased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 80.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,186 shares of the company's stock after selling 56,817 shares during the quarter. Headlands Technologies LLC's holdings in Hims & Hers Health were worth $419,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in HIMS. LPL Financial LLC lifted its holdings in Hims & Hers Health by 1.0% in the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company's stock worth $2,369,000 after buying an additional 980 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new position in Hims & Hers Health in the 4th quarter worth $208,000. National Bank of Canada FI lifted its holdings in Hims & Hers Health by 438.7% in the 4th quarter. National Bank of Canada FI now owns 2,990 shares of the company's stock worth $72,000 after buying an additional 2,435 shares in the last quarter. Aviva PLC acquired a new position in Hims & Hers Health in the 4th quarter worth $550,000. Finally, Envestnet Asset Management Inc. lifted its holdings in Hims & Hers Health by 139.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock worth $1,903,000 after buying an additional 45,791 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded down $0.09 during trading on Wednesday, reaching $47.87. The company had a trading volume of 3,549,619 shares, compared to its average volume of 34,073,082. The firm's fifty day moving average is $53.39 and its 200 day moving average is $45.30. The firm has a market capitalization of $10.72 billion, a PE ratio of 59.66, a price-to-earnings-growth ratio of 3.16 and a beta of 2.08. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The company's revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.06 earnings per share. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent analyst reports. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Truist Financial upped their target price on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $39.83.

Insider Activity at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the sale, the insider directly owned 169,940 shares of the company's stock, valued at $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Chi sold 2,100 shares of the stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total transaction of $120,792.00. Following the sale, the insider directly owned 278,654 shares of the company's stock, valued at approximately $16,028,178.08. This represents a 0.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,460,276 shares of company stock valued at $77,374,454. 17.71% of the stock is currently owned by insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.